Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20109
Título
Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine
Autor(es)
Fecha de publicación
2015-04
Cita
Payeras Cifre A, Villoslada Gelabert A, Garau Colom MM, Salvador MN, Gallegos Alvarez MC. Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine. Int J Infect Dis. 2015 Apr;33:22-7. Epub 2014 Dec 23.
Idioma
Inglés
Tipo de documento
research article
Resumen
Objectives: To describe the distribution of vaccine and non-vaccine pneumococcal serotypes from adult patients for different clinical scenarios, after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV-13) for children. Methods: This was a prospective study of pneumococcal infections in adult patients (January 2010 to April 2014) in Hospital Son Llatzer, Mallorca (Spain). Two different periods of time were compared, the first before (first period) and the second after (second period) the introduction of PCV-13. Information related to clinical characteristics, outcomes of infection, pneumococcal serotypes, and antibiotic susceptibility was collected. Results: We studied 407 episodes (371 patients), 201 in the first period and 206 in the second period. The majority of patients were male; the median patient age was 68 (range 15-99) years. Infections due to PCV-13 serotypes decreased from 59.7% to 47.6% (p = 0.014), mainly serotypes 3, 7, 18C, 19F, and 23F. In the second period, PCV-13 serotypes were the cause of pneumonia in 58.2% of cases and in 40.8% of invasive infections, but these serotypes were not related with any outcome variable. No differences in hospital or intensive care unit admission, severity, or mortality were observed between the two periods. Susceptibility to penicillin (98.2% vs. 95.1%, p = 0.03) and amoxicillin (96.5% vs. 91%, p = 0.007) was slightly higher in the first period. Conclusions: Although a reduction in infections due to vaccine serotypes was observed, close to half of infections in adult patients were caused by PCV-13 serotypes. Even after pediatric vaccination with PCV-13, vaccine serotypes were still responsible for most pneumonia and invasive disease, underscoring the importance of implementing current guidelines and extending vaccination to other risk groups.
Palabras clave
Pneumococcal pneumonia | Pneumococcal invasive disease | Pneumococcal conjugate vaccines | Clinical features | Outcome
MESH
Child | Aged, 80 and over | Aged | Young Adult | Serogroup | Adult | Anti-Bacterial Agents | Humans | Child, Preschool | Adolescent | Pneumococcal Vaccines | Middle Aged | Infant | Male | Infant, Newborn | Prospective Studies | Pneumococcal Infections | Female | Streptococcus pneumoniae | Vaccination
DECS
Streptococcus pneumoniae | Serogrupo | Vacunación | Recién Nacido | Femenino | Lactante | Vacunas Neumococicas | Adolescente | Masculino | Preescolar | Infecciones Neumocócicas | Humanos | Persona de Mediana Edad | Estudios Prospectivos | Adulto Joven | Anciano | Anciano de 80 o más Años | Niño | Adulto | Antibacterianos
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-ShareAlike 4.0 International
Ítems relacionados
Mostrando ítems relacionados por Título, autor o palabras clave.
-
2020-09-29
research article
Miguel, Sara de ISCIII; Domenech Lucas, Mirian ISCIII; Gonzalez-Camacho, Fernando ISCIII; et al.